Do not stop using these drugs without first consulting with your physician.
FDA announced a required label change for several fluoroquinolone drugs
Fluoroquinolone antibiotics (FLQ) have the unique ability to penetrate the blood-brain barrier, entering the brain and damaging the central nervous system.
Many of these drugs have already been removed from the market due to their toxicity, and those that remain are riddled with black box warnings required by the U.S. Food and Drug Administration (FDA).
In 2003, after numerous reports of patients developing symptoms of nerve damage and long-lasting peripheral neuropathy, the FDA began investigating the association between FLQ drugs and peripheral neuropathy. It has since been proven that FLQ antibiotics carry a significant risk of causing nerve damage in the hands, feet, arms or legs.
In 2013, the FDA released a Safety Communication warning with required label changes for several fluoroquinolone drugs including Cipro, Avelox, Factive, Levaquin and Noroxin to warn of an increased risk for permanent nerve damage from antibacterial fluoroquinolone drugs taken by mouth or by injection. The FDA stated that current fluoroquinolone warnings were not clear enough.
FDA Safety Alerts
In May 2016, the FDA announced a required label change for fluoroquinolones after an internal safety review found the drug class to be associated with “disabling and potentially permanent, serious side effects that can occur together when used by tablet, capsules, or injection.
"[ 05-12-2016 ] The U.S. Food and Drug Administration is advising that the serious side effects associated with fluoroquinolone antibacterial drugs generally outweigh the benefits for patients with acute sinusitis, acute bronchitis, and uncomplicated urinary tract infections who have other treatment options. For patients with these conditions, fluoroquinolones should be reserved for those who do not have alternative treatment "
Patients were warned to contact their healthcare provider immediately with symptoms such as “tendon, joint and muscle pain, a pins and needles tingling or pricking sensation, confusion, and hallucinations.” Healthcare providers were warned to stop systemic FLQ treatments immediately in cases where a patient reports such symptoms and recommended that they “switch to a non-fluoroquinolone antibacterial drug to complete the patient’s treatment course.”
According to plaintiffs in a federal lawsuit filed in the District of Columbia, pharmaceutical giant Johnson & Johnson, the manufacturer of Levaquin, hid details about the drug’s adverse side effects.
Lawsuits are alleging that the drug manufacturer failed to warn consumers and the medical community about the potential side effect of permanent peripheral neuropathy.
FLQ (FLUOROQUINOLONES) Lawsuit Eligibiity Check
Financial compensation may be available for people who have suffered from severe side effects after taking FLQ antibiotics.
If you or your loved one has suffered from aortic dissection, aortic aneurysm or nerve damage due to use of Levaquin, Avelox, or Cipro antibiotics, please contact us immediately to see if you are qualified.
The lawyers in our legal network have the required knowledge to review the facts of your situation to help determine if you are eligible to file a lawsuit against FLQ manufacturers and distributors. Attorneys within Relion Group Legal Network provide free consultations.

If your answers meet the requirements for a FLQ lawsuit, you may be eligible to receive financial compensation for your injuries upon resolution of your case.